Advertisement
ABBV vs MRK
Which Stock Would AI Choose? AbbVie (ABBV) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- Both ABBV and MRK delivered better-than-expected third-quarter results and raised full-year guidance, but their growth profiles and risk exposures differ sharply.
- AbbVie is compounding double-digit revenue growth across immunology and neuroscience, while Merck remains heavily dependent on its Keytruda oncology franchise ahead of a 2028 patent cliff.
- AbbVie has successfully transitioned past the Humira patent expiration, whereas Merck's diversification is still unfolding and carries more execution risk.
- Tickeron AI Verdict: The AI favors ABBV for its more consistent trend, broader growth drivers, and lower single-asset concentration risk relative to MRK.
- For additional context, explore ABBV Major News and ABBV Today's Price Move, as well as MRK Major News and MRK Today's Price Move.
- To see how automated strategies are positioning across the market, explore the Trending AI Robots page.
Introduction
AbbVie (ABBV) and Merck & Co. (MRK) are two of the largest pharmaceutical companies in the world, but they occupy different positions in the industry's growth cycle. Both are frequent holdings for income-oriented and defensive investors, yet their relative performance has diverged as AbbVie executes a post-patent-cliff recovery and Merck races to diversify before its flagship oncology drug loses exclusivity. This stock comparison is relevant for long-term investors, dividend seekers, and traders evaluating healthcare exposure who want to understand how market positioning, growth drivers, and risk factors differ between the two names.
ABBV Overview and Recent Performance
ABBV is a global, research-driven biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics. In recent weeks, the company reported revenue of roughly $17.4 billion, up about 10% year over year, and raised its full-year outlook for the third time this year. Growth has been led by its next-generation immunology drugs Skyrizi and Rinvoq, which posted gains of about 23% and 24%, respectively, more than offsetting a steep decline in legacy blockbuster Humira. The neuroscience franchise also accelerated, growing nearly 20% on strength from Vraylar, Ubrelvy, and Qulipta. Management also raised the quarterly dividend modestly and closed the Apogee Therapeutics acquisition, which adds dermatology and respiratory assets. The market's positive reaction reflects confidence that AbbVie has successfully replaced its legacy revenue base.
MRK Overview and Recent Performance
MRK is a diversified pharmaceutical and animal health company whose results remain anchored by the cancer immunotherapy Keytruda. In its most recent quarter, the company reported sales of about $18.1 billion, up 5%, with adjusted earnings that comfortably beat consensus and full-year guidance that was raised. Keytruda and its newer under-the-skin formulation, Keytruda Qlex, generated roughly $8.6 billion, while the pulmonary arterial hypertension treatment Winrevair nearly doubled to $694 million and the HPV (human papillomavirus) vaccine Gardasil rebounded. However, the company acknowledged that a portion of its growth reflected favorable purchasing timing, and profit declined year over year as expenses rose. The key investor question remains how effectively Merck can sustain momentum as Keytruda approaches its 2028 loss of exclusivity.
Trending AI Robots
Tickeron maintains hundreds of AI Trading Bots that trade thousands of different tickers, but only the strategies best suited to current market conditions earn a place in the curated Trending AI Robots section. These automated systems span a wide range of trading styles, timeframes, performance statistics, and sets of tickers, so no single bot fits every investor. The page surfaces the bots that are currently demonstrating the strongest alignment with prevailing market dynamics, making it a useful starting point for traders researching data-driven approaches. Explore the Trending AI Robots page to review the available strategies and their recent performance.
Head-to-Head Comparison
From a business-model perspective, AbbVie is a more concentrated biopharmaceutical play with a clear lead in immunology and an emerging neuroscience franchise, while Merck spans oncology, vaccines, and animal health. In terms of growth, AbbVie is compounding revenue at roughly twice Merck's rate, driven by newer products that are still scaling. Merck, by contrast, is more dependent on a single franchise, which heightens concentration risk ahead of the 2028 Keytruda patent expiration. On relative performance, both stocks have rallied strongly over the past year, but AbbVie's trajectory has been steadier, whereas Merck's has been more sensitive to headline events such as cancer vaccine data releases. Risk profiles also differ: AbbVie faces pressure from biosimilar competition and government drug pricing rules, while Merck must contend with generic erosion, patent expiry, and heavier R&D spending. From a market positioning standpoint, AbbVie's diversification is more mature, while Merck's diversification is promising but less proven.
Tickeron AI Verdict
Based on observable factors including trend consistency, breadth of growth drivers, and relative concentration risk, Tickeron's AI would currently lean toward ABBV. The company's steadier momentum, triple guidance increases, successful navigation of the Humira patent cliff, and multiple double-digit growth engines present a more balanced risk-reward profile than MRK's heavier dependence on Keytruda ahead of its patent expiration. While Merck's pipeline and newer products offer meaningful upside, they also carry greater execution uncertainty. The AI's preference for AbbVie reflects a probabilistic assessment of relative stability and positioning rather than a definitive forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and MRK is a Buy.
Aroon Indicator for ABBV shows an upward move is likely
ABBV's Aroon Indicator triggered a bullish signal on November 12, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 353 similar instances where the Aroon Indicator showed a similar pattern. In 226 of the 353 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 49 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
Following a +0.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 222 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 69 cases where ABBV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 45%.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 21 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 44%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
MRK sees its Stochastic Oscillator climbs out of oversold territory
On October 30, 2026, the Stochastic Oscillator for MRK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In 37 of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MRK as a result. In 53 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 30, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 24 of 50 cases over the following month. The odds of a continued upward trend are 48%.
MRK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MRK crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 172 of 265 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.633) is normal, around the industry mean (-1.421). MRK's P/E Ratio (116.452) is considerably higher than the industry average of (21.700). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
ABBV | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | 29 | |
SMR RATING 1..100 | 1 | 79 | |
PRICE GROWTH RATING 1..100 | 13 | 15 | |
P/E GROWTH RATING 1..100 | 91 | 1 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (88). This means that ABBV’s stock grew significantly faster than MRK’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as MRK (29). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (79). This means that ABBV’s stock grew significantly faster than MRK’s over the last 12 months.
ABBV's Price Growth Rating (13) in the Pharmaceuticals Major industry is in the same range as MRK (15). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (91). This means that MRK’s stock grew significantly faster than ABBV’s over the last 12 months.
| ABBV | MRK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 40% | N/A |
| Stochastic ODDS (%) | 1 day ago 45% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 63% |
| MACD ODDS (%) | 1 day ago 44% | 1 day ago 48% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 57% |
| Advances ODDS (%) | 2 days ago 61% | 14 days ago 57% |
| Declines ODDS (%) | 10 days ago 46% | 1 day ago 51% |
| BollingerBands ODDS (%) | 1 day ago 39% | N/A |
| Aroon ODDS (%) | 1 day ago 64% | 1 day ago 65% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while MRK’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 3 TA indicator(s) are bullish while MRK’s TA Score has 7 bullish TA indicator(s).
- ABBV’s TA Score: 3 bullish, 5 bearish.
- MRK’s TA Score: 7 bullish, 1 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +2.15% price change this week, while MRK (@Pharmaceuticals: Major) price change was +0.01% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.08%. For the same industry, the average monthly price growth was +4.08%, and the average quarterly price growth was +6.57%.
Reported Earning Dates
ABBV is expected to report earnings on Feb 03, 2027.
MRK is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+1.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.18% | ||
| NVS - ABBV | 52% Loosely correlated | -0.04% | ||
| JNJ - ABBV | 51% Loosely correlated | +1.11% | ||
| BMY - ABBV | 50% Loosely correlated | -0.94% | ||
| AMGN - ABBV | 49% Loosely correlated | -0.22% | ||
| GILD - ABBV | 47% Loosely correlated | -1.05% | ||
More | ||||
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.